New study provides physical basis for raised levels of serotonin in autism

From Volume 4 Number 11

NASHVILLE, Tennessee, USA:  Many children with autism have elevated blood levels of serotonin – a chemical with strong links to mood and anxiety. But what relevance this "hyperserotonemia" has for autism has remained a mystery.
    New research by Vanderbilt University Medical Center investigators provides a physical basis for this phenomenon, which may have profound implications for the origin of some autism-associated deficits.
    In an advance online publication in the Journal of Clinical Investigation, Dr Ana Carneiro and colleagues report that a well-known protein found in blood platelets, integrin beta3, physically associates with and regulates the serotonin transporter (SERT), a protein that controls serotonin availability.
     Serotonin has long been suspected to play a role in autism since elevated blood serotonin and genetic variations in the SERT have been linked to autism.
    Alterations in brain serotonin have also been associated with anxiety, depression and alcoholism; antidepressants that block SERT (known as SSRIs, or selective serotonin re-uptake inhibitors) block SERT's ability to sweep synapses clean of serotonin.
    Working in the lab of Dr Randy Blakely, Dr Carneiro was searching for proteins that interact with SERT that might contribute to disorders where serotonin signalling is altered.
    "Levels of SERT in the brain are actually quite low, so we decided to see what progress we could make with peripheral cells that have much higher quantities, said Dr Blakely, the Allan D. Bass Professor of Pharmacology and director of the Vanderbilt Center for Molecular Neuroscience. "This took us to platelets."
     In platelets, SERTs accumulate serotonin produced in the gut. SSRIs or genetic deletion of SERT in animals prevents serotonin uptake in the platelet.
      Prior research had fingered the integrin beta3 gene as a determinant of blood serotonin levels and, independently, as a risk factor for autism, Dr Blakely said.
       In the current study, Dr Carneiro identified a large set of proteins that "stick" to SERT, presuming they might control SERT activity. One of these turned out to be integrin beta3.
    Once they confirmed a physical relationship between the two proteins, Dr Blakely's team investigated whether the interaction can change SERT activity. They found that cells lacking integrin beta3 exhibit reduced serotonin uptake and that integrin beta3
activation or a human integrin beta3 mutation greatly enhances serotonin uptake.
    "We found that integrin beta3 can put the serotonin transporter into high gear," said Dr Blakely. Notably, Dr Edwin Cook, at the University of Chicago and a co-author on the study, had shown that the same integrin beta3 mutation that elevates SERT activity also predicts elevated blood serotonin.
    "Most investigators studying this integrin beta3 mutation have focused on how its high activity state changes platelet clotting and never looked at its impact on serotonin levels or SERT function," explained Dr Carneiro. "Now they have a reason to."
    "We don't think the platelet itself contributes to autism," said Dr Blakely, "but rather we believe that the brain's serotonin transporter may be controlled by integrin proteins in a very similar manner."
    Dr Carneiro and Dr Blakely believe that too much SERT activity imposed by abnormal integrin interactions could restrict availability of serotonin in the brain during development, as well as in the adult.
    "What is even more striking is that this is the second time we have found elevated SERT activity associated with autism," said Dr Blakely. In a 2005 study, Dr Blakely and a Vanderbilt collaborator, Dr James Sutcliffe,  identified mutations in the SERT gene that triggered elevated SERT activity.
    Dr Carneiro is now hot on the trail of integrin interactions with brain SERT as well as engineering mice that express human integrin beta3 mutations.
       At a February Keystone Conference, Dr Blakely described preliminary studies with mice that his lab has engineered to express hyperactive SERT mutations.
    "Together, these new animal models offer an unprecedented opportunity to peel away the complexity of autism and possibly develop new therapies," he said.
    This research may also uncover new ways of treating depression. "Current anti-depressant mechanisms still essentially work in the same way they did 25 years ago – by targeting transporter uptake of neurotransmitter directly," Dr Carneiro said. "Now we may have a completely new way to go about it."

Looking Up, 16-page English PDF Edition, Back Issues and Current Issue

Looking Up, Volume 5 Number 1 PDF edition front cover Looking Up, Volume 5 Number 2 PDF edition front cover Looking Up, Volume 5 Number 3 PDF edition front cover Looking Up, Volume 5 Number 4 PDF edition front cover
Looking Up, Volume 5 Number 5 PDF edition front cover Looking Up, Volume 5 Number 6 PDF edition front cover Looking Up, Volume 5 Number 7 PDF edition front cover Looking Up, Volume 5 Number 8 PDF edition front cover

Current 40-page print edition issue
Current print edition of Looking Up

HOW TO CONTACT US

Email (general enquiries):Info@lookingupautism.org
Email (subscription/order enquiries):    Subscriptions@lookingupautism.org
Postal address:Looking Up, PO Box 25727, London, SW19 1WF, UK
Telephone (London, UK):+44-208-5427702, or 0208-5427702 from the UK
FAX (UK):+44-871-3140327, or 0871-3140327 from the UK
Our Home Page:http://www.lookingupautism.org

Search our autism pages

PRINT EDITION BACK ISSUE CONTENTS AND FRONT COVERS
VOLUME 1, Number: 1 2 3 4 5 6 7 8 9 10 11 12   VOLUME 2, Number: 1 2 3 4 5 6 7 8 9 10 11 12
VOLUME 3, Number: 1 2 3 4 5 6 7 8 9 10 11 12   VOLUME 4, Number: 1 2 3 4 5 6 7 8 9 10 11 12
VOLUME 5, Number: 1 2 3 4 5 6 7 8
You can find our PDF EDITION CONTENTS AND COVERS on our PDF EDITION BACK ISSUES PAGE

Privacy

We use third-party advertising companies to serve ads when you visit our website. These companies may use information (not including your name, address, email address or telephone number) about your visits to this and other websites in order to provide advertisements about goods and services of interest to you. If you would like more information about this practice and would like to know your options in relation to·not having this information used by these companies, click here.

Copyright declaration

Materials available from these web pages are copyright © AFPublications.org unless otherwise stated.